05 Jan MIC’s Notable Deliveries of 2022
Dear Colleagues,
It’s always interesting to look back at the work we did in the preceding year. Here are some reflections on 2022 as a founder of MIC. The Year 2022 has been a very busy and exciting year for us. We have been blessed with wonderful opportunities this year.
In line with the vision of the company, MIC was constantly focussing on clinical and drug development, strategies, and medical monitoring with innovative ways and finding solutions for our clients to carve out a niche for itself in these services. In the last 1 year, we were part of multiple key milestones that includes submission of EOP2 to the USFDA, IND submissions, medical monitoring of the studies in the US and Europe for solid tumors and haematological malignancies, due diligence activities, and publications of the NCE molecules and monoclonal antibodies in high-indexed, peer-reviewed journals.
We are sincerely grateful to our colleagues and friends who helped us achieve a high standard of quality and value. We are also grateful to our clients who over the years have always believed in our expertise and scientific knowledge. All these achievements could not be done without you.
Hoping to continue our journey in 2023!
Dr Mohini Barde, MD
Sorry, the comment form is closed at this time.